{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:53:10Z","timestamp":1791031990998,"version":"4.1.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1538_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Sitagliptin is a standard therapeutic option for type 2 diabetes mellitus (T2DM), while metoprolol is an antihypertensive agent. This study aimed to assess the safety of their combination therapy in elderly patients with T2DM and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1538_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical data of 52 elderly patients with T2DM and hypertension from June 2021 to March 2024 were retrospectively collected. According to different treatment methods, 52 patients were categorized into the sitagliptin + metoprolol group (n=26) and the sitagliptin group (n=26). After a 12-week treatment period, the baseline characteristics, therapeutic efficacy and biochemical indicators were analyzed between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1538_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 12-week treatment, both groups exhibited significant improvements in therapeutic efficacy, immune-inflammatory status, coagulation function, and liver-kidney function (p&lt;0.05). Compared with the sitagliptin group, the sitagliptin + metoprolol group showed better therapeutic efficacy, with lower FPG, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , SBP, and DBP levels (p&lt;0.05). The combination group also achieved greater improvements in immune-inflammation, coagulation, and liver-kidney function (lower CRP, NLR, Fib, Scr and BUN, as well as higher PT and APTT) (p&lt;0.05). There was no significant difference in incidence of adverse event between the two groups (p&gt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1538_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term observation indicates that sitagliptin combined with metoprolol can improve blood glucose, blood pressure, inflammation, coagulation, and liver-kidney function in elderly patients with T2DM and hypertension, without a significant increase in the risk of adverse reactions during short-term follow-up. However, as a single-center, small-sample retrospective study, the present findings should be interpreted as preliminary clinical evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1538","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:06:29Z","timestamp":1791029189000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety study of sitagliptin combined with metoprolol on the treatment of elderly patients with type 2 diabetes mellitus and hypertension"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4890-6445","authenticated-orcid":false,"given":"Xiaoqing","family":"Dai","sequence":"first","affiliation":[{"name":"General Practice, Tianshui-Wulin Sub-district Community Health Service Center , Hangzhou City , Zhejiang Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6380-1487","authenticated-orcid":false,"given":"Jiali","family":"Yu","sequence":"additional","affiliation":[{"name":"General Practice, Tianshui-Wulin Sub-district Community Health Service Center , Hangzhou City , Zhejiang Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100312062204836_j_med-2026-1538_ref_001","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia, U, Benito-Vicente, A, Jebari, S, Larrea-Sebal, A, Siddiqi, H, Uribe, KB, et al.. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci 2020;21:6275. https:\/\/doi.org\/10.3390\/ijms21176275.","DOI":"10.3390\/ijms21176275"},{"key":"2026100312062204836_j_med-2026-1538_ref_002","doi-asserted-by":"crossref","unstructured":"Egbuna, C, Awuchi, CG, Kushwaha, G, Rudrapal, M, Patrick-Iwuanyanwu, KC, Singh, O, et al.. Bioactive compounds effective against type 2 diabetes mellitus: a systematic review. Curr Top Med Chem 2021;21:1067\u201395. https:\/\/doi.org\/10.2174\/1568026621666210509161059.","DOI":"10.2174\/1568026621666210509161059"},{"key":"2026100312062204836_j_med-2026-1538_ref_003","doi-asserted-by":"crossref","unstructured":"Chen, K, Gao, Z, Ding, Q, Tang, C, Zhang, H, Zhai, T, et al.. Effect of natural polyphenols in Chinese herbal medicine on obesity and diabetes: interactions among gut microbiota, metabolism, and immunity. Front Nutr 2022;9:962720. https:\/\/doi.org\/10.3389\/fnut.2022.962720.","DOI":"10.3389\/fnut.2022.962720"},{"key":"2026100312062204836_j_med-2026-1538_ref_004","doi-asserted-by":"crossref","unstructured":"Zhou, S, Dai, YM, Zeng, XF, Chen, HZ. Circadian clock and sirtuins in diabetic lung: a mechanistic perspective. Front Endocrinol 2020;11:173. https:\/\/doi.org\/10.3389\/fendo.2020.00173.","DOI":"10.3389\/fendo.2020.00173"},{"key":"2026100312062204836_j_med-2026-1538_ref_005","doi-asserted-by":"crossref","unstructured":"Bulum, T, Tomi\u0107, M, Vrabec, R, Brklja\u010di\u0107, N, Ljubi\u0107, S. Systolic and diastolic blood pressure are independent risk factors for diabetic retinopathy in patients with type 2 diabetes. Biomedicines 2023;11:2242. https:\/\/doi.org\/10.3390\/biomedicines11082242.","DOI":"10.3390\/biomedicines11082242"},{"key":"2026100312062204836_j_med-2026-1538_ref_006","doi-asserted-by":"crossref","unstructured":"Wang, XN, Sim, BR, Chen, H, Zheng, YX, Xue, JB, Wang, L, et al.. Identification of sitagliptin binding proteins by affinity purification mass spectrometry. Acta Biochim Biophys Sin 2022;54:1453\u201363. https:\/\/doi.org\/10.3724\/abbs.2022142.","DOI":"10.3724\/abbs.2022142"},{"key":"2026100312062204836_j_med-2026-1538_ref_007","doi-asserted-by":"crossref","unstructured":"Qi, JH, Chen, PY, Cai, DY, Wang, Y, Wei, YL, He, SP, et al.. Exploring novel targets of sitagliptin for type 2 diabetes mellitus: network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches. Front Endocrinol 2022;13:1096655. https:\/\/doi.org\/10.3389\/fendo.2022.1096655.","DOI":"10.3389\/fendo.2022.1096655"},{"key":"2026100312062204836_j_med-2026-1538_ref_008","doi-asserted-by":"crossref","unstructured":"Kutoh, E, Kuto, AN, Wada, A, Hayashi, J, Kurihara, R. Sitagliptin as an initial therapy and differential regulations of metabolic parameters depending on its glycemic response in subjects with type 2 diabetes. Drug Res 2021;71:157\u201365. https:\/\/doi.org\/10.1055\/a-1304-3430.","DOI":"10.1055\/a-1304-3430"},{"key":"2026100312062204836_j_med-2026-1538_ref_009","doi-asserted-by":"crossref","unstructured":"Brocker, CN, Velenosi, T, Flaten, HK, McWilliams, G, McDaniel, K, Shelton, SK, et al.. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genom 2020;14:10. https:\/\/doi.org\/10.1186\/s40246-020-00260-w.","DOI":"10.1186\/s40246-020-00260-w"},{"key":"2026100312062204836_j_med-2026-1538_ref_010","doi-asserted-by":"crossref","unstructured":"Huang, Y, Liu, XL, Wen, J, Huang, LH, Lu, Y, Miao, RJ, et al.. Downregulation of the \u03b21 adrenergic receptor in the myocardium results in insensitivity to metoprolol and reduces blood pressure in spontaneously hypertensive rats. Mol Med Rep 2017;15:703\u201311. https:\/\/doi.org\/10.3892\/mmr.2016.6038.","DOI":"10.3892\/mmr.2016.6038"},{"key":"2026100312062204836_j_med-2026-1538_ref_011","doi-asserted-by":"crossref","unstructured":"Khamis, AM. Pathophysiology, diagnostic criteria, and approaches to type 2 diabetes remission. Cureus 2023;15:e33908. https:\/\/doi.org\/10.7759\/cureus.33908.","DOI":"10.7759\/cureus.33908"},{"key":"2026100312062204836_j_med-2026-1538_ref_012","doi-asserted-by":"crossref","unstructured":"Malta, DC, Gon\u00e7alves, RPF, Machado, \u00cdE, Freitas, MIF, Azeredo, C, Szwarcwald, CL. Prevalence of arterial hypertension according to different diagnostic criteria, National Health Survey. Revista brasileira de epidemiologia = Braz J Epidemiol 2018;21:e180021. https:\/\/doi.org\/10.1590\/1980-549720180021.","DOI":"10.1590\/1980-549720180021.supl.1"},{"key":"2026100312062204836_j_med-2026-1538_ref_013","unstructured":"Ping, TZ, Gu, DL. Clinical observation of sitagliptin combined with \u03b2 -blockers in the treatment of patients with type 2 diabetes mellitus complicated with coronary heart disease. J\u00a0Pract Diabetol 2020;16:1."},{"key":"2026100312062204836_j_med-2026-1538_ref_014","doi-asserted-by":"crossref","unstructured":"Khan, RMM, Chua, ZJY, Tan, JC, Yang, Y, Liao, Z, Zhao, Y. From pre-diabetes to diabetes: diagnosis, treatments and translational research. Medicina (Kaunas, Lithuania) 2019;55:546. https:\/\/doi.org\/10.3390\/medicina55090546.","DOI":"10.3390\/medicina55090546"},{"key":"2026100312062204836_j_med-2026-1538_ref_015","doi-asserted-by":"crossref","unstructured":"Wang, M, Hng, TM. HbA1c: more than just a number. Aust J Gen Pract 2021;50:628\u201332. https:\/\/doi.org\/10.31128\/ajgp-03-21-5866.","DOI":"10.31128\/AJGP-03-21-5866"},{"key":"2026100312062204836_j_med-2026-1538_ref_016","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, A, Kim, JY, Reyes, JA, Vander Wyst, KB, Ayers, SL, Olson, ML, et al.. Changes in OGTT-derived biomarkers in response to lifestyle intervention among Latino adolescents with obesity. Pediatr Obes 2022;17:e12867. https:\/\/doi.org\/10.1111\/ijpo.12867.","DOI":"10.1111\/ijpo.12867"},{"key":"2026100312062204836_j_med-2026-1538_ref_017","doi-asserted-by":"crossref","unstructured":"Mak, WY, Nagarajah, JR, Abdul Halim, H, Ramadas, A, Mohd Pauzi, Z, Pee, LT, et al.. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital. J\u00a0Pharm Policy Pract 2020;13:34. https:\/\/doi.org\/10.1186\/s40545-020-00238-y.","DOI":"10.1186\/s40545-020-00238-y"},{"key":"2026100312062204836_j_med-2026-1538_ref_018","unstructured":"Shi, CH, Wang, L, Bai, R, Wang, YB, Liu, D, Zhang, XY, et al.. Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes. Zhonghua yi xue za zhi 2016;96:2554\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2016.32.008."},{"key":"2026100312062204836_j_med-2026-1538_ref_019","doi-asserted-by":"crossref","unstructured":"Mu, L, Yu, P, Xu, H, Gong, T, Chen, D, Tang, J, et al.. Effect of sodium reduction based on the DASH diet on blood pressure in hypertensive patients with type 2 diabetes. Nutr Hosp 2022;39:537\u201346. https:\/\/doi.org\/10.20960\/nh.04039.","DOI":"10.20960\/nh.04039"},{"key":"2026100312062204836_j_med-2026-1538_ref_020","doi-asserted-by":"crossref","unstructured":"Wang, Z, Chen, Z, Wang, X, Hao, G, Ma, L, Zhao, X, et al.. Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. J\u00a0Hypertens 2017;35:886\u201392. https:\/\/doi.org\/10.1097\/hjh.0000000000001209.","DOI":"10.1097\/HJH.0000000000001209"},{"key":"2026100312062204836_j_med-2026-1538_ref_021","doi-asserted-by":"crossref","unstructured":"Wang, S, Pan, X, Jia, B, Chen, S. Exploring the correlation between the systemic immune inflammation index (SII), Systemic Inflammatory Response Index (SIRI), and type 2 diabetic retinopathy. Diabetes, Metab Syndrome Obes Targets Ther 2023;16:3827\u201336. https:\/\/doi.org\/10.2147\/dmso.s437580.","DOI":"10.2147\/DMSO.S437580"},{"key":"2026100312062204836_j_med-2026-1538_ref_022","doi-asserted-by":"crossref","unstructured":"Bian, X, He, J, Zhang, R, Yuan, S, Dou, K. The combined effect of systemic immune-inflammation index and type 2 diabetes mellitus on the prognosis of patients undergoing percutaneous coronary intervention: a large-scale cohort study. J\u00a0Inflamm Res 2023;16:6415\u201329. https:\/\/doi.org\/10.2147\/jir.s445479.","DOI":"10.2147\/JIR.S445479"},{"key":"2026100312062204836_j_med-2026-1538_ref_023","doi-asserted-by":"crossref","unstructured":"Guo, W, Song, Y, Sun, Y, Du, H, Cai, Y, You, Q, et al.. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: evidence from NHANES 2011-2018. Front Endocrinol 2022;13:1071465. https:\/\/doi.org\/10.3389\/fendo.2022.1071465.","DOI":"10.3389\/fendo.2022.1071465"},{"key":"2026100312062204836_j_med-2026-1538_ref_024","doi-asserted-by":"crossref","unstructured":"Kocaaslan, R, Dilli, D, \u00c7itli, R. Diagnostic value of the systemic immune-inflammation index in newborns with urinary tract infection. Am J Perinatol 2024;41:e719\u201327. https:\/\/doi.org\/10.1055\/s-0042-1757353.","DOI":"10.1055\/s-0042-1757353"},{"key":"2026100312062204836_j_med-2026-1538_ref_025","unstructured":"Li, Y, Li, L, Ou, M, Xu, X, Li, M, Chen, C. Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus. Zhong nan da xue xue bao Yi xue ban = J Cent S Univ Med Sci 2015;40:1186\u201391. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2015.11.004."},{"key":"2026100312062204836_j_med-2026-1538_ref_026","doi-asserted-by":"crossref","unstructured":"Liu, W, Zhu, J, Cheng, J, Tang, Q, Long, S. Relationship between platelet index and lipid metabolism, coagulation function, and inflammation in diabetic patients. Clin Lab 2024;70. https:\/\/doi.org\/10.7754\/Clin.Lab.2023.230635.","DOI":"10.7754\/Clin.Lab.2023.230635"},{"key":"2026100312062204836_j_med-2026-1538_ref_027","doi-asserted-by":"crossref","unstructured":"Pan, L, Ye, Y, Wo, M, Bao, D, Zhu, F, Cheng, M, et al.. Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis Markers 2018;2018:5214376\u20137. https:\/\/doi.org\/10.1155\/2018\/5214376.","DOI":"10.1155\/2018\/5214376"},{"key":"2026100312062204836_j_med-2026-1538_ref_028","doi-asserted-by":"crossref","unstructured":"Zhang, CJ, Meyer, SR, O\u2019Meara, MJ, Huang, S, Capeling, MM, Ferrer-Torres, D, et al.. A human liver organoid screening platform for DILI risk prediction. J\u00a0Hepatol 2023;78:998\u20131006. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.019.","DOI":"10.1016\/j.jhep.2023.01.019"},{"key":"2026100312062204836_j_med-2026-1538_ref_029","doi-asserted-by":"crossref","unstructured":"Li, X, Liao, J, Su, X, Li, W, Bi, Z, Wang, J, et al.. Human urine-derived stem cells protect against renal ischemia\/reperfusion injury in a rat model via exosomal miR-146a-5p which targets IRAK1. Theranostics 2020;10:9561\u201378. https:\/\/doi.org\/10.7150\/thno.42153.","DOI":"10.7150\/thno.42153"},{"key":"2026100312062204836_j_med-2026-1538_ref_030","doi-asserted-by":"crossref","unstructured":"Shahbaz, A, Aziz, K, Umair, M, Sharifzadeh, M, Sachmechi, I. Acute liver injury induced by sitagliptin: report of two cases and review of literature. Cureus 2018;10:e2776. https:\/\/doi.org\/10.7759\/cureus.2776.","DOI":"10.7759\/cureus.2776"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1538\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:06:39Z","timestamp":1791029199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1538\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1538"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1538","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261538"}}